NEWS

OncLive Peer Exchange Mentions I-SPY Trial in Neoadjuvant T-DM1 in HER2+ Early Breast Cancer Discussion

Panelists: Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute; Ahmad Awada, MD, PhD, Jules Bordet Institute; Wolfgang J. Janni, MD, PhD, University of Ulm; Hope S. Rugo, MD, UCSF Helen Diller Family Comprehensive Cancer Center; Michael Untch, MD, Helios Klinikum Berlin-Buch

Neoadjuvant T-DM1 in HER2+ Early Breast Cancer

Panelists Adam M. Brufsky, MD, PhD; Hope S. Rugo, MD; Michael Untch, MD; and Ahmad Awada, MD, PhD, describe the use of neoadjuvant T-DM1 in HER2+ early breast cancer.